Nunaps
PrivateLast Round
Series B
Jan 1, 2025
Total Funding Raised
$13.47M
Company Overview
Nunaps operates in Healthcare & Life Sciences and is based in Seoul. Its latest recorded funding round was a Series B round in January 2025.
Nunaps is a digital therapeutics company that develops software-based medical devices and platforms to treat and manage neurological disorders.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Medical AI, Clinical Trials, AR/VR Experiences
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nunaps Comparables
Compare Nunaps with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Emocog | 78% | |
| S-Alpha Therapeutics | 77% | |
| HAII | 76% |
For institutional investors. Book with your work email.
Nunaps Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 1, 2025 | ||||
| Series A | Jan 5, 2020 | ||||
| Seed | Dec 1, 2017 |
For institutional investors. Book with your work email.
Nunaps Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hanwha Investment & Securities | Series B |
| K2 Investment Partners | Series A |
| Smilegate Investment | Series B |
| Prodigy Investment | VC Round |
| Company K Partners | Seed, Series A, Series B |
| Woori Venture Partners Co., Ltd. | Series B |
| Korea Development Bank | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 17, 2026
Grew 200% QoQ, from 2 to 6 employees.
- Mar 14, 2026
Grew 500% QoQ from 1 to 6 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingAug 18, 2026
Nunaps Inc. secures $15.5M through Series B financing in South Korea, bringing its total secured funding to KRW21.9b (US$16m).
- is_developingAug 18, 2026
Nunaps Inc. is developing Lexure, a digital therapeutic for patients with language disorders, in South Korea.
For institutional investors. Book with your work email.
Nunaps Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nunaps's valuation, stock price, and market status.
Is Nunaps a public or private company?
Nunaps is a private company.
What is the current stock price of Nunaps?
Nunaps is a private company, so its shares have no public market price. Caplight tracks Nunaps's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nunaps worth (valuation)?
Valuation information for Nunaps is not publicly available.
Can I buy Nunaps stock?
Nunaps shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nunaps's last funding round?
Nunaps's most recent funding round was Series B on January 1, 2025.
Who are the main investors in Nunaps?
Key investors in Nunaps include Hanwha Investment & Securities, K2 Investment Partners, Smilegate Investment, Prodigy Investment, Company K Partners.
Will Nunaps IPO soon?
No public IPO plans have been announced for Nunaps.
How can I track Nunaps secondary market activity?
Caplight tracks bids, offers, and trades in Nunaps's shares on secondary markets.